Expanding the Potential of TCR-Based T-Cell Engagers into Infectious Diseases
- Sharing early clinical data on TCR-based bispecific molecules developed to treat HBV and HIV
- Analyzing the pharmacokinetics and pharmacodynamics associated with this mechanism of action
- Highlighting the differences from oncology that emerge due to a lack of suppressive tumor microenvironment